Ovarian cancer (OC), the most lethal gynaecological cancer, will result in ~13,000 deaths in the UK this year. At time of diagnosis most patients (58%) present with an advanced stage (III or IV) and 5-year survival is 27% for stage III and 13% for stage IV ovarian cancer in which chemotherapy is still the principal treatment for OC patients. Repurposing drug screens with compounds that have already gained FDA approval can accelerate the identification of new therapies to treat an illness and in the cancer setting extend life or provide compassionate care. This research project will focus on investigating drug combinations of novel interacting compounds to identify new therapeutic strategies to treat OC from existing FDA approved drug libraries. Research will focus on evaluating the pharmacology of drug combinations and elucidation of the underlying tumour characteristics associated with a good/poor response to these drugs. In this PhD, we will employ routine cell and molecular biology techniques to study the drug responses in cancer cell models. You will gain experience in RNAi and protein over-expression techniques, the study of intracellular signalling and a variety of in vitro assays to measure key hallmarks of tumorigenesis and drug responses in cancer cell lines and primary cultures. Novel results will be tested in in vivo models and/or clinically relevant samples.
Based on your current searches we recommend the following search filters.